| 1 |
2022 |
Angeles C. Tecalco-Cruz, Marina Macías-Silva, Josué Orlando Ramírez-Jarquín, Uri Nimrod Ramírez-Jarquín. Decoding the Therapeutic Implications of the ERα Stability and Subcellular Distribution in Breast Cancer, Frontiers in Endocrinology. 2022; 13: 867448.
https://doi.org/10.3389/fendo.2022.867448 |
| 2 |
2025 |
Alina Goerg, Gerhard Piendl, Veruschka Albert, Olaf Ortmann, Anja Kathrin Wege, Gero Brockhoff. Mdm2 targeting via PROteolysis TArgeting Chimeras (PROTAC) is efficient in p53 wildtype, p53-mutated, and abemaciclib-resistant estrogen receptor-positive cell lines and superior to mdm2 inhibition, BMC Cancer. 2025; 25: 978.
https://doi.org/10.1186/s12885-025-14361-z |
| 3 |
2024 |
Zhenjie Wang, Siyao Che, Zhiqiang Yu. PROTAC: Novel degradable approach for different targets to treat breast cancer, European Journal of Pharmaceutical Sciences. 2024; 198: 106793106793.
https://doi.org/10.1016/j.ejps.2024.106793 |
| 4 |
2022 |
Zi Liu, Mingxing Hu, Yu Yang, Chenghao Du, Haoxuan Zhou, Chengyali Liu, Yuanwei Chen, Lei Fan, Hongqun Ma, Youling Gong, Yongmei Xie. An overview of PROTACs: a promising drug discovery paradigm, Molecular Biomedicine. 2022; 3: 46.
https://doi.org/10.1186/s43556-022-00112-0 |
| 5 |
2023 |
Hannah L. Chang, Blake Schwettmann, Heather L. McArthur, Isaac S. Chan. Antibody-drug conjugates in breast cancer: overcoming resistance and boosting immune response, Journal of Clinical Investigation. 2023; 133: e172156.
https://doi.org/10.1172/JCI172156 |
